+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Clinical Trials Market in US 2023-2027

  • PDF Icon

    Report

  • 148 Pages
  • October 2023
  • Region: United States
  • TechNavio
  • ID: 5892866
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The clinical trials market in US is forecasted to grow by USD 5.9 bn during 2022-2027, accelerating at a CAGR of 5.3% during the forecast period. The report on the clinical trials market in US provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by a rise in a number of clinical trials of drugs, the rise in the adoption of artificial intelligence (AI)-based tools for drug delivery, and the growing demand for personalized medicine and targeted therapies.

The clinical trials market in US is segmented as below:

By Type

  • Phase III
  • Phase I
  • Phase II
  • Phase IV

By Service Type

  • Interventional studies
  • Observational studies
  • Expanded access studies

By Indication

  • Oncology
  • CNS
  • Autoimmune/Inflammation
  • Cardiovascular and others
This study identifies the advancement in technology and scientific research as one of the prime reasons driving the clinical trials market in US growth during the next few years. Also, rise in outsourcing of clinical trial process and growing investment in healthcare and pharmaceutical industries will lead to sizable demand in the market.

The report on the clinical trials market in US covers the following areas:

  • Clinical trials market in US sizing
  • Clinical trials market in US forecast
  • Clinical trials market in US industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading clinical trials market in US vendors that include Medpace Holdings Inc., Laboratory Corp. of America Holdings, Sanofi, CTI Clinical Trial and Consulting Inc., ICON plc, Syneos Health Inc., IQVIA Holdings Inc., Charles River Laboratories International Inc., Parexel International Corp., Pfizer Inc., Thermo Fisher Scientific Inc., Caidya, Accell Clinical Research LLC, Clinipace Inc., eResearchTechnology GmbH, Apex Medical Research Inc., WuXi AppTec Co. Ltd., Novartis AG, Novo Nordisk AS, and Eli Lilly and Co.. Also, the clinical trials market in US analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Country Market Characteristics
Exhibit 04: Executive Summary - Chart on Market Segmentation by Type
Exhibit 05: Executive Summary - Chart on Market Segmentation by Service Type
Exhibit 06: Executive Summary - Chart on Market Segmentation by Indication
Exhibit 07: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 08: Parent market
Exhibit 09: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 10: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 11: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 12: Chart on US - Market size and forecast 2022-2027 ($ billion)
Exhibit 13: Data Table on US - Market size and forecast 2022-2027 ($ billion)
Exhibit 14: Chart on US: Year-over-year growth 2022-2027 (%)
Exhibit 15: Data Table on US: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
4.1 Clinical trials market in US 2017 - 2021
Exhibit 16: Historic Market Size - Data Table on clinical trials market in US 2017 - 2021 ($ billion)
4.2 Type Segment Analysis 2017 - 2021
Exhibit 17: Historic Market Size - Type Segment 2017 - 2021 ($ billion)
4.3 Service Type Segment Analysis 2017 - 2021
Exhibit 18: Historic Market Size - Service Type Segment 2017 - 2021 ($ billion)
4.4 Indication Segment Analysis 2017 - 2021
Exhibit 19: Historic Market Size - Indication Segment 2017 - 2021 ($ billion)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 20: Five forces analysis - Comparison between 2022 and 2027
5.2 Bargaining power of buyers
Exhibit 21: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
5.3 Bargaining power of suppliers
Exhibit 22: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
5.4 Threat of new entrants
Exhibit 23: Threat of new entrants - Impact of key factors in 2022 and 2027
5.5 Threat of substitutes
Exhibit 24: Threat of substitutes - Impact of key factors in 2022 and 2027
5.6 Threat of rivalry
Exhibit 25: Threat of rivalry - Impact of key factors in 2022 and 2027
5.7 Market condition
Exhibit 26: Chart on Market condition - Five forces 2022 and 2027
6 Market Segmentation by Type
6.1 Market segments
Exhibit 27: Chart on Type - Market share 2022-2027 (%)
Exhibit 28: Data Table on Type - Market share 2022-2027 (%)
6.2 Comparison by Type
Exhibit 29: Chart on Comparison by Type
Exhibit 30: Data Table on Comparison by Type
6.3 Phase III - Market size and forecast 2022-2027
Exhibit 31: Chart on Phase III - Market size and forecast 2022-2027 ($ billion)
Exhibit 32: Data Table on Phase III - Market size and forecast 2022-2027 ($ billion)
Exhibit 33: Chart on Phase III - Year-over-year growth 2022-2027 (%)
Exhibit 34: Data Table on Phase III - Year-over-year growth 2022-2027 (%)
6.4 Phase I - Market size and forecast 2022-2027
Exhibit 35: Chart on Phase I - Market size and forecast 2022-2027 ($ billion)
Exhibit 36: Data Table on Phase I - Market size and forecast 2022-2027 ($ billion)
Exhibit 37: Chart on Phase I - Year-over-year growth 2022-2027 (%)
Exhibit 38: Data Table on Phase I - Year-over-year growth 2022-2027 (%)
6.5 Phase II - Market size and forecast 2022-2027
Exhibit 39: Chart on Phase II - Market size and forecast 2022-2027 ($ billion)
Exhibit 40: Data Table on Phase II - Market size and forecast 2022-2027 ($ billion)
Exhibit 41: Chart on Phase II - Year-over-year growth 2022-2027 (%)
Exhibit 42: Data Table on Phase II - Year-over-year growth 2022-2027 (%)
6.6 Phase IV - Market size and forecast 2022-2027
Exhibit 43: Chart on Phase IV - Market size and forecast 2022-2027 ($ billion)
Exhibit 44: Data Table on Phase IV - Market size and forecast 2022-2027 ($ billion)
Exhibit 45: Chart on Phase IV - Year-over-year growth 2022-2027 (%)
Exhibit 46: Data Table on Phase IV - Year-over-year growth 2022-2027 (%)
6.7 Market opportunity by Type
Exhibit 47: Market opportunity by Type ($ billion)
Exhibit 48: Data Table on Market opportunity by Type ($ billion)
7 Market Segmentation by Service Type
7.1 Market segments
Exhibit 49: Chart on Service Type - Market share 2022-2027 (%)
Exhibit 50: Data Table on Service Type - Market share 2022-2027 (%)
7.2 Comparison by Service Type
Exhibit 51: Chart on Comparison by Service Type
Exhibit 52: Data Table on Comparison by Service Type
7.3 Interventional studies - Market size and forecast 2022-2027
Exhibit 53: Chart on Interventional studies - Market size and forecast 2022-2027 ($ billion)
Exhibit 54: Data Table on Interventional studies - Market size and forecast 2022-2027 ($ billion)
Exhibit 55: Chart on Interventional studies - Year-over-year growth 2022-2027 (%)
Exhibit 56: Data Table on Interventional studies - Year-over-year growth 2022-2027 (%)
7.4 Observational studies - Market size and forecast 2022-2027
Exhibit 57: Chart on Observational studies - Market size and forecast 2022-2027 ($ billion)
Exhibit 58: Data Table on Observational studies - Market size and forecast 2022-2027 ($ billion)
Exhibit 59: Chart on Observational studies - Year-over-year growth 2022-2027 (%)
Exhibit 60: Data Table on Observational studies - Year-over-year growth 2022-2027 (%)
7.5 Expanded access studies - Market size and forecast 2022-2027
Exhibit 61: Chart on Expanded access studies - Market size and forecast 2022-2027 ($ billion)
Exhibit 62: Data Table on Expanded access studies - Market size and forecast 2022-2027 ($ billion)
Exhibit 63: Chart on Expanded access studies - Year-over-year growth 2022-2027 (%)
Exhibit 64: Data Table on Expanded access studies - Year-over-year growth 2022-2027 (%)
7.6 Market opportunity by Service Type
Exhibit 65: Market opportunity by Service Type ($ billion)
Exhibit 66: Data Table on Market opportunity by Service Type ($ billion)
8 Market Segmentation by Indication
8.1 Market segments
Exhibit 67: Chart on Indication - Market share 2022-2027 (%)
Exhibit 68: Data Table on Indication - Market share 2022-2027 (%)
8.2 Comparison by Indication
Exhibit 69: Chart on Comparison by Indication
Exhibit 70: Data Table on Comparison by Indication
8.3 Oncology - Market size and forecast 2022-2027
Exhibit 71: Chart on Oncology - Market size and forecast 2022-2027 ($ billion)
Exhibit 72: Data Table on Oncology - Market size and forecast 2022-2027 ($ billion)
Exhibit 73: Chart on Oncology - Year-over-year growth 2022-2027 (%)
Exhibit 74: Data Table on Oncology - Year-over-year growth 2022-2027 (%)
8.4 CNS - Market size and forecast 2022-2027
Exhibit 75: Chart on CNS - Market size and forecast 2022-2027 ($ billion)
Exhibit 76: Data Table on CNS - Market size and forecast 2022-2027 ($ billion)
Exhibit 77: Chart on CNS - Year-over-year growth 2022-2027 (%)
Exhibit 78: Data Table on CNS - Year-over-year growth 2022-2027 (%)
8.5 Autoimmune/inflammation - Market size and forecast 2022-2027
Exhibit 79: Chart on Autoimmune/inflammation - Market size and forecast 2022-2027 ($ billion)
Exhibit 80: Data Table on Autoimmune/inflammation - Market size and forecast 2022-2027 ($ billion)
Exhibit 81: Chart on Autoimmune/inflammation - Year-over-year growth 2022-2027 (%)
Exhibit 82: Data Table on Autoimmune/inflammation - Year-over-year growth 2022-2027 (%)
8.6 Cardiovascular and others - Market size and forecast 2022-2027
Exhibit 83: Chart on Cardiovascular and others - Market size and forecast 2022-2027 ($ billion)
Exhibit 84: Data Table on Cardiovascular and others - Market size and forecast 2022-2027 ($ billion)
Exhibit 85: Chart on Cardiovascular and others - Year-over-year growth 2022-2027 (%)
Exhibit 86: Data Table on Cardiovascular and others - Year-over-year growth 2022-2027 (%)
8.7 Market opportunity by Indication
Exhibit 87: Market opportunity by Indication ($ billion)
Exhibit 88: Data Table on Market opportunity by Indication ($ billion)
9 Customer Landscape
9.1 Customer landscape overview
Exhibit 89: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 90: Impact of drivers and challenges in 2022 and 2027
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 91: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 92: Overview on factors of disruption
11.4 Industry risks
Exhibit 93: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 94: Vendors covered
12.2 Market positioning of vendors
Exhibit 95: Matrix on vendor position and classification
12.3 Accell Clinical Research LLC
Exhibit 96: Accell Clinical Research LLC - Overview
Exhibit 97: Accell Clinical Research LLC - Key offerings
12.4 Caidya
Exhibit 98: Caidya - Overview
Exhibit 99: Caidya - Key offerings
12.5 Charles River Laboratories International Inc.
Exhibit 100: Charles River Laboratories International Inc. - Overview
Exhibit 101: Charles River Laboratories International Inc. - Business segments
Exhibit 102: Charles River Laboratories International Inc. - Key news
Exhibit 103: Charles River Laboratories International Inc. - Key offerings
Exhibit 104: Charles River Laboratories International Inc. - Segment focus
12.6 Clinipace Inc.
Exhibit 105: Clinipace Inc. - Overview
Exhibit 106: Clinipace Inc. - Product/Service
Exhibit 107: Clinipace Inc. - Key offerings
12.7 CTI Clinical Trial and Consulting Inc.
Exhibit 108: CTI Clinical Trial and Consulting Inc. - Overview
Exhibit 109: CTI Clinical Trial and Consulting Inc. - Product/Service
Exhibit 110: CTI Clinical Trial and Consulting Inc. - Key offerings
12.8 Eli Lilly and Co.
Exhibit 111: Eli Lilly and Co. - Overview
Exhibit 112: Eli Lilly and Co. - Product/Service
Exhibit 113: Eli Lilly and Co. - Key news
Exhibit 114: Eli Lilly and Co. - Key offerings
12.9 ICON plc
Exhibit 115: ICON plc - Overview
Exhibit 116: ICON plc - Product/Service
Exhibit 117: ICON plc - Key offerings
12.10 IQVIA Holdings Inc.
Exhibit 118: IQVIA Holdings Inc. - Overview
Exhibit 119: IQVIA Holdings Inc. - Business segments
Exhibit 120: IQVIA Holdings Inc. - Key news
Exhibit 121: IQVIA Holdings Inc. - Key offerings
Exhibit 122: IQVIA Holdings Inc. - Segment focus
12.11 Laboratory Corp. of America Holdings
Exhibit 123: Laboratory Corp. of America Holdings - Overview
Exhibit 124: Laboratory Corp. of America Holdings - Business segments
Exhibit 125: Laboratory Corp. of America Holdings - Key news
Exhibit 126: Laboratory Corp. of America Holdings - Key offerings
Exhibit 127: Laboratory Corp. of America Holdings - Segment focus
12.12 Medpace Holdings Inc.
Exhibit 128: Medpace Holdings Inc. - Overview
Exhibit 129: Medpace Holdings Inc. - Product/Service
Exhibit 130: Medpace Holdings Inc. - Key offerings
12.13 Parexel International Corp.
Exhibit 131: Parexel International Corp. - Overview
Exhibit 132: Parexel International Corp. - Product/Service
Exhibit 133: Parexel International Corp. - Key news
Exhibit 134: Parexel International Corp. - Key offerings
12.14 Pfizer Inc.
Exhibit 135: Pfizer Inc. - Overview
Exhibit 136: Pfizer Inc. - Product/Service
Exhibit 137: Pfizer Inc. - Key news
Exhibit 138: Pfizer Inc. - Key offerings
12.15 Sanofi
Exhibit 139: Sanofi - Overview
Exhibit 140: Sanofi - Business segments
Exhibit 141: Sanofi - Key news
Exhibit 142: Sanofi - Key offerings
Exhibit 143: Sanofi - Segment focus
12.16 Syneos Health Inc.
Exhibit 144: Syneos Health Inc. - Overview
Exhibit 145: Syneos Health Inc. - Business segments
Exhibit 146: Syneos Health Inc. - Key offerings
Exhibit 147: Syneos Health Inc. - Segment focus
12.17 Thermo Fisher Scientific Inc.
Exhibit 148: Thermo Fisher Scientific Inc. - Overview
Exhibit 149: Thermo Fisher Scientific Inc. - Business segments
Exhibit 150: Thermo Fisher Scientific Inc. - Key news
Exhibit 151: Thermo Fisher Scientific Inc. - Key offerings
Exhibit 152: Thermo Fisher Scientific Inc. - Segment focus
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 153: Inclusions checklist
Exhibit 154: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 155: Currency conversion rates for US$
13.4 Research methodology
Exhibit 156: Research methodology
Exhibit 157: Validation techniques employed for market sizing
Exhibit 158: Information sources
13.5 List of abbreviations
Exhibit 159: List of abbreviations
List of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Country Market Characteristics
Exhibits 4: Executive Summary - Chart on Market Segmentation by Type
Exhibits 5: Executive Summary - Chart on Market Segmentation by Service Type
Exhibits 6: Executive Summary - Chart on Market Segmentation by Indication
Exhibits 7: Executive Summary - Chart on Vendor Market Positioning
Exhibits 8: Parent market
Exhibits 9: Market Characteristics
Exhibits 10: Offerings of vendors included in the market definition
Exhibits 11: Market segments
Exhibits 12: Chart on US - Market size and forecast 2022-2027 ($ billion)
Exhibits 13: Data Table on US - Market size and forecast 2022-2027 ($ billion)
Exhibits 14: Chart on US: Year-over-year growth 2022-2027 (%)
Exhibits 15: Data Table on US: Year-over-year growth 2022-2027 (%)
Exhibits 16: Historic Market Size - Data Table on clinical trials market in US 2017 - 2021 ($ billion)
Exhibits 17: Historic Market Size - Type Segment 2017 - 2021 ($ billion)
Exhibits 18: Historic Market Size - Service Type Segment 2017 - 2021 ($ billion)
Exhibits 19: Historic Market Size - Indication Segment 2017 - 2021 ($ billion)
Exhibits 20: Five forces analysis - Comparison between 2022 and 2027
Exhibits 21: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
Exhibits 22: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
Exhibits 23: Threat of new entrants - Impact of key factors in 2022 and 2027
Exhibits 24: Threat of substitutes - Impact of key factors in 2022 and 2027
Exhibits 25: Threat of rivalry - Impact of key factors in 2022 and 2027
Exhibits 26: Chart on Market condition - Five forces 2022 and 2027
Exhibits 27: Chart on Type - Market share 2022-2027 (%)
Exhibits 28: Data Table on Type - Market share 2022-2027 (%)
Exhibits 29: Chart on Comparison by Type
Exhibits 30: Data Table on Comparison by Type
Exhibits 31: Chart on Phase III - Market size and forecast 2022-2027 ($ billion)
Exhibits 32: Data Table on Phase III - Market size and forecast 2022-2027 ($ billion)
Exhibits 33: Chart on Phase III - Year-over-year growth 2022-2027 (%)
Exhibits 34: Data Table on Phase III - Year-over-year growth 2022-2027 (%)
Exhibits 35: Chart on Phase I - Market size and forecast 2022-2027 ($ billion)
Exhibits 36: Data Table on Phase I - Market size and forecast 2022-2027 ($ billion)
Exhibits 37: Chart on Phase I - Year-over-year growth 2022-2027 (%)
Exhibits 38: Data Table on Phase I - Year-over-year growth 2022-2027 (%)
Exhibits 39: Chart on Phase II - Market size and forecast 2022-2027 ($ billion)
Exhibits 40: Data Table on Phase II - Market size and forecast 2022-2027 ($ billion)
Exhibits 41: Chart on Phase II - Year-over-year growth 2022-2027 (%)
Exhibits 42: Data Table on Phase II - Year-over-year growth 2022-2027 (%)
Exhibits 43: Chart on Phase IV - Market size and forecast 2022-2027 ($ billion)
Exhibits 44: Data Table on Phase IV - Market size and forecast 2022-2027 ($ billion)
Exhibits 45: Chart on Phase IV - Year-over-year growth 2022-2027 (%)
Exhibits 46: Data Table on Phase IV - Year-over-year growth 2022-2027 (%)
Exhibits 47: Market opportunity by Type ($ billion)
Exhibits 48: Data Table on Market opportunity by Type ($ billion)
Exhibits 49: Chart on Service Type - Market share 2022-2027 (%)
Exhibits 50: Data Table on Service Type - Market share 2022-2027 (%)
Exhibits 51: Chart on Comparison by Service Type
Exhibits 52: Data Table on Comparison by Service Type
Exhibits 53: Chart on Interventional studies - Market size and forecast 2022-2027 ($ billion)
Exhibits 54: Data Table on Interventional studies - Market size and forecast 2022-2027 ($ billion)
Exhibits 55: Chart on Interventional studies - Year-over-year growth 2022-2027 (%)
Exhibits 56: Data Table on Interventional studies - Year-over-year growth 2022-2027 (%)
Exhibits 57: Chart on Observational studies - Market size and forecast 2022-2027 ($ billion)
Exhibits 58: Data Table on Observational studies - Market size and forecast 2022-2027 ($ billion)
Exhibits 59: Chart on Observational studies - Year-over-year growth 2022-2027 (%)
Exhibits 60: Data Table on Observational studies - Year-over-year growth 2022-2027 (%)
Exhibits 61: Chart on Expanded access studies - Market size and forecast 2022-2027 ($ billion)
Exhibits 62: Data Table on Expanded access studies - Market size and forecast 2022-2027 ($ billion)
Exhibits 63: Chart on Expanded access studies - Year-over-year growth 2022-2027 (%)
Exhibits 64: Data Table on Expanded access studies - Year-over-year growth 2022-2027 (%)
Exhibits 65: Market opportunity by Service Type ($ billion)
Exhibits 66: Data Table on Market opportunity by Service Type ($ billion)
Exhibits 67: Chart on Indication - Market share 2022-2027 (%)
Exhibits 68: Data Table on Indication - Market share 2022-2027 (%)
Exhibits 69: Chart on Comparison by Indication
Exhibits 70: Data Table on Comparison by Indication
Exhibits 71: Chart on Oncology - Market size and forecast 2022-2027 ($ billion)
Exhibits 72: Data Table on Oncology - Market size and forecast 2022-2027 ($ billion)
Exhibits 73: Chart on Oncology - Year-over-year growth 2022-2027 (%)
Exhibits 74: Data Table on Oncology - Year-over-year growth 2022-2027 (%)
Exhibits 75: Chart on CNS - Market size and forecast 2022-2027 ($ billion)
Exhibits 76: Data Table on CNS - Market size and forecast 2022-2027 ($ billion)
Exhibits 77: Chart on CNS - Year-over-year growth 2022-2027 (%)
Exhibits 78: Data Table on CNS - Year-over-year growth 2022-2027 (%)
Exhibits 79: Chart on Autoimmune/inflammation - Market size and forecast 2022-2027 ($ billion)
Exhibits 80: Data Table on Autoimmune/inflammation - Market size and forecast 2022-2027 ($ billion)
Exhibits 81: Chart on Autoimmune/inflammation - Year-over-year growth 2022-2027 (%)
Exhibits 82: Data Table on Autoimmune/inflammation - Year-over-year growth 2022-2027 (%)
Exhibits 83: Chart on Cardiovascular and others - Market size and forecast 2022-2027 ($ billion)
Exhibits 84: Data Table on Cardiovascular and others - Market size and forecast 2022-2027 ($ billion)
Exhibits 85: Chart on Cardiovascular and others - Year-over-year growth 2022-2027 (%)
Exhibits 86: Data Table on Cardiovascular and others - Year-over-year growth 2022-2027 (%)
Exhibits 87: Market opportunity by Indication ($ billion)
Exhibits 88: Data Table on Market opportunity by Indication ($ billion)
Exhibits 89: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 90: Impact of drivers and challenges in 2022 and 2027
Exhibits 91: Overview on Criticality of inputs and Factors of differentiation
Exhibits 92: Overview on factors of disruption
Exhibits 93: Impact of key risks on business
Exhibits 94: Vendors covered
Exhibits 95: Matrix on vendor position and classification
Exhibits 96: Accell Clinical Research LLC - Overview
Exhibits 97: Accell Clinical Research LLC - Key offerings
Exhibits 98: Caidya - Overview
Exhibits 99: Caidya - Key offerings
Exhibits 100: Charles River Laboratories International Inc. - Overview
Exhibits 101: Charles River Laboratories International Inc. - Business segments
Exhibits 102: Charles River Laboratories International Inc. - Key news
Exhibits 103: Charles River Laboratories International Inc. - Key offerings
Exhibits 104: Charles River Laboratories International Inc. - Segment focus
Exhibits 105: Clinipace Inc. - Overview
Exhibits 106: Clinipace Inc. - Product/Service
Exhibits 107: Clinipace Inc. - Key offerings
Exhibits 108: CTI Clinical Trial and Consulting Inc. - Overview
Exhibits 109: CTI Clinical Trial and Consulting Inc. - Product/Service
Exhibits 110: CTI Clinical Trial and Consulting Inc. - Key offerings
Exhibits 111: Eli Lilly and Co. - Overview
Exhibits 112: Eli Lilly and Co. - Product/Service
Exhibits 113: Eli Lilly and Co. - Key news
Exhibits 114: Eli Lilly and Co. - Key offerings
Exhibits 115: ICON plc - Overview
Exhibits 116: ICON plc - Product/Service
Exhibits 117: ICON plc - Key offerings
Exhibits 118: IQVIA Holdings Inc. - Overview
Exhibits 119: IQVIA Holdings Inc. - Business segments
Exhibits 120: IQVIA Holdings Inc. - Key news
Exhibits 121: IQVIA Holdings Inc. - Key offerings
Exhibits 122: IQVIA Holdings Inc. - Segment focus
Exhibits 123: Laboratory Corp. of America Holdings - Overview
Exhibits 124: Laboratory Corp. of America Holdings - Business segments
Exhibits 125: Laboratory Corp. of America Holdings - Key news
Exhibits 126: Laboratory Corp. of America Holdings - Key offerings
Exhibits 127: Laboratory Corp. of America Holdings - Segment focus
Exhibits 128: Medpace Holdings Inc. - Overview
Exhibits 129: Medpace Holdings Inc. - Product/Service
Exhibits 130: Medpace Holdings Inc. - Key offerings
Exhibits 131: Parexel International Corp. - Overview
Exhibits 132: Parexel International Corp. - Product/Service
Exhibits 133: Parexel International Corp. - Key news
Exhibits 134: Parexel International Corp. - Key offerings
Exhibits 135: Pfizer Inc. - Overview
Exhibits 136: Pfizer Inc. - Product/Service
Exhibits 137: Pfizer Inc. - Key news
Exhibits 138: Pfizer Inc. - Key offerings
Exhibits 139: Sanofi - Overview
Exhibits 140: Sanofi - Business segments
Exhibits 141: Sanofi - Key news
Exhibits 142: Sanofi - Key offerings
Exhibits 143: Sanofi - Segment focus
Exhibits 144: Syneos Health Inc. - Overview
Exhibits 145: Syneos Health Inc. - Business segments
Exhibits 146: Syneos Health Inc. - Key offerings
Exhibits 147: Syneos Health Inc. - Segment focus
Exhibits 148: Thermo Fisher Scientific Inc. - Overview
Exhibits 149: Thermo Fisher Scientific Inc. - Business segments
Exhibits 150: Thermo Fisher Scientific Inc. - Key news
Exhibits 151: Thermo Fisher Scientific Inc. - Key offerings
Exhibits 152: Thermo Fisher Scientific Inc. - Segment focus
Exhibits 153: Inclusions checklist
Exhibits 154: Exclusions checklist
Exhibits 155: Currency conversion rates for US$
Exhibits 156: Research methodology
Exhibits 157: Validation techniques employed for market sizing
Exhibits 158: Information sources
Exhibits 159: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the clinical trials market in US: Medpace Holdings Inc., Laboratory Corp. of America Holdings, Sanofi, CTI Clinical Trial and Consulting Inc., ICON plc, Syneos Health Inc., IQVIA Holdings Inc., Charles River Laboratories International Inc., Parexel International Corp., Pfizer Inc., Thermo Fisher Scientific Inc., Caidya, Accell Clinical Research LLC, Clinipace Inc., eResearchTechnology GmbH, Apex Medical Research Inc., WuXi AppTec Co. Ltd., Novartis AG, Novo Nordisk AS, and Eli Lilly and Co..

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is advancement in technology and scientific research.'

According to the report, one of the major drivers for this market is the rise in number of clinical trials of drugs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Medpace Holdings Inc.
  • Laboratory Corp. of America Holdings
  • Sanofi
  • CTI Clinical Trial and Consulting Inc.
  • ICON plc
  • Syneos Health Inc.
  • IQVIA Holdings Inc.
  • Charles River Laboratories International Inc.
  • Parexel International Corp.
  • Pfizer Inc.
  • Thermo Fisher Scientific Inc.
  • Caidya
  • Accell Clinical Research LLC
  • Clinipace Inc.
  • eResearchTechnology GmbH
  • Apex Medical Research Inc.
  • WuXi AppTec Co. Ltd.
  • Novartis AG
  • Novo Nordisk AS
  • Eli Lilly and Co.

Related Topics

Related Reports

Global Clinical Trials Market Report and Forecast 2023-2031 - Product Image

Global Clinical Trials Market Report and Forecast 2023-2031

  • Report
  • 147 Pages
  • Global
From
Global Clinical Trials Connect 2024 (London, United Kingdom - May 28-29, 2024) - Product Image

Global Clinical Trials Connect 2024 (London, United Kingdom - May 28-29, 2024)

  • Conference
  • 2 Days
  • Global
Global Preclinical CRO Market 2023-2027 - Product Image

Global Preclinical CRO Market 2023-2027

  • Report
  • 152 Pages
  • Global
From
Global Clinical Trial Supplies Market 2023-2027 - Product Image

Global Clinical Trial Supplies Market 2023-2027

  • Report
  • 162 Pages
  • Global
From
US Clinical Trials Support Services Market - Focused Insights 2023-2028 - Product Image

US Clinical Trials Support Services Market - Focused Insights 2023-2028

  • Report
  • 97 Pages
  • United States
From

About the Clinical Trials Market

The Clinical Trials market is a sector of the healthcare industry that focuses on the development and testing of new treatments and medications. Clinical trials are conducted in order to assess the safety and efficacy of new drugs and treatments, and to determine the best dosage and method of administration. Clinical trials are conducted in phases, with each phase designed to answer specific questions about the drug or treatment. The results of clinical trials are used to inform regulatory decisions about the approval of new drugs and treatments. The Clinical Trials market is composed of a variety of companies, including pharmaceutical companies, contract research organizations, and clinical research organizations. These companies are responsible for designing, conducting, and analyzing clinical trials. Some of the major players in the Clinical Trials market include Parexel, Quintiles, Covance, ICON, and PPD. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.